-+ 0.00%
-+ 0.00%
-+ 0.00%

Danish Pharma H. Lundbeck Expects No Slowdown for Primary Growth Driver Brands

MT Newswires·08/19/2026 07:27:01
Listen to the news
07:27 AM EDT, 08/19/2026 (MT Newswires) -- H. Lundbeck's (HLUN-A.CO, HLUN-B.CO) Chief Executive Officer Charl van Zyl said he sees no signs of a slowdown in demand for the company's migraine-preventing infusion treatment Vyepti and antipsychotic drug Rexulti, Reuters reported Wednesday. The outlook for the Danish pharmaceutical company's key growth brands comes as it reiterated its 2026 revenue growth guidance of 7% to 9% at constant exchange rates alongside its first-half report.